Swiss Re’s Alnylam Pharmaceuticals ALNY Stock Holding History

Swiss Re’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30	Closed	-$9.93K	–	242
2026 Q1	$9.93K	Hold	30	–	–	0.06%	219
2025 Q4	$11.9K	Buy	+30	New	+$13.3K	﹤0.01%	203

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Swiss Re's ALNY Position: Q2 2026 in Review

Swiss Re sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 30 shares — an estimated $9.93K sold.

Swiss Re first reported a position in ALNY in Q4 2025 and held it in 2 quarters. The position peaked at $11.9K in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Swiss Re reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Swiss Re sold 30 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $9.93K.
Swiss Re first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Swiss Re's Alnylam Pharmaceuticals position peaked at $11.9K in Q4 2025.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Swiss Re's 13F filing for Q2 2026, filed 11 Aug 2026.